Prevention and surveillance of infection after liver transplantation

Current Opinion in Critical Care

Volumn 4, Issue 5, 1998, Pages 293-302

  Linden, Peter ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0040599021     PISSN: 10705295     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075198-199810000-00006     Document Type: Article

References (102)

1. Seaberg EC, Belle SH, Beringer KC, Schivins JL, Detre KM: Long-term patient and retransplantation-free survival by selected recipient and donor characteristics: an update from the Pitt-UNOS liver transplant registry. In Clinical Transplants 1997, edn 13. Edited by Cecka JM, Terasaki PI. Los Angeles: 1998:15-28.
2. Winston DG, Emmanouilides C, Busuttil RW: Infections in liver transplant recipients. Clin Infect Dis 1995; 21:1077-1091.
3. Patel R, Paya CV: Infections in solid-organ transplant recipients. Clin Microbiol Rev 1997, 10:86-124. This is a comprehensive review of infectious complications in the solid-organ transplant population with more than 700 references.
4. Silva AE, Hosein B, Boyle RW, Fang CT, Shindo M, Waggoner JG, et al: Diagnosis of chronic hepatitis C: comparison of immunoassays and the polymerase chain reaction. Am J Gastroenterol 1994, 89:493-496.
5. Pawlotsky JM, Lonjon I, Hezode C, Raynard B, Darthuy F, Remire J, et al: What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories. Hepatology 1998, 27:1700-1702.
6. Caudai C, Padula MG, Bastiannoni I, Valensin PE, Shyamala V, Han J, et al: Antibody testing and RT-PCR results in hepatitis C virus (HCV) infection: HCV-RNA detection in PBMC of plasma viremia-negative HCV-seropositive persons. Infection 1998, 26:151-154.
7. Guarner C, Soriano G: Spontaneous bacterial peritonitis. Semin Liver Dis 1997, 17:203-217.
8. Castellone J, Xiol X, Verdaguer R, Ribes J, Guardiola J, Gimenez A, Casais L: Comparison of two ascitic fluid culture methods in cirrhotic patients with spontaneous bacterial peritonitis. Am J Gastroenterol 1990, 85:1605-1608.
9. Bac DL, de Marie S, Siersema PD, Spobl J, van Buuren HR: Post-sclerotherapy bacterial peritonitis: a complication of sclerotherapy or of variceal bleeding? Am J Gastroenterol 1994, 89:859-862.
10. Soriano G, Guarner C, Tomas A, Villanueva C, Torras Y, Gonzalez D, et al: Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage. Gastroenterology 1991, 100:477-781.
11. Rolachon A, Cordier L, Bacq Y, Nousbaum JB, Franza A, Paris JC, et al: Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis in cirrhosis: results of a prospective controlled trial. Hepatology 1995, 22:1171-1174.
12. Singh N, Gayowski T, Yu VL, Wagener MM: Trimethoprim-sulfamethoxasole for the prevention of spontaneous bacterial peritonitis in cirrhosis: a randomized trial. Ann Intern Med 1995, 122:595-598.
13. Ortiz J, Soriano G, Sola R, et al: Characteristics of the infections caused by Escherichia coli resistant to norfloxacin in hospitalized cirrhotic patients. Hepatology 1995, 22:166A.
14. Loinaz C, de Juanes JR, Gonzalez EM, Lopez A, Lumbreras C, Gomez R, et al: Hepatitis B vaccination results in 140 liver transplant recipients. Hepatogastroenterology 1997, 44:235-238.
15. Chang FY, Singh N, Gayowski T, Wagener MM, Marino IR: Fever in liver transplant recipients: changing spectrum of etiologic agents. Clin Infect Dis 1998, 26:59-65.
16. Singh N, Gayowski T, Marino IR: Causes of leukocytosis in liver transplant recipients: relevance in clinical practice. Transplantation 1998, 65:199-203.
17. Gayowski T, Marino IR, Singh N, Doyle H, Wagener M, Fung JJ, Starzl TE: Orthotopic liver transplantation in high-risk patients: risk factors associated with mortality and infectious morbidity. Transplantation 1998, 65:499-504.
18. Barkholt LM, Andersson J, Ericzon BG, Palmgren AC, Brome U, Duraj F, et al: Stool cultures obtained before liver transplantation are useful for choice of perioperative antibiotic prophylaxis. Transplant Int 1997, 10:432-438.
19. Kuo PC, Bartlett ST, Lim JW, Plotkin JS, Wilson S, Johnson LB: Selective bowel decontamination in hospitalized patients awaiting liver transplantation. Am J Surg 1997, 174:745-748.
20. Wiesner RH, Hermans PE, Rakela J, Perkins J, Washington J, DiCecco S, Krom RAF: Selective bowel decontamination to decrease gram-negative aerobic bacterial and Candida colonization and prevent infection after orthotopic liver transplantation. Transplantation 1988, 45:570-574.
21. Badger IL, Crosby HA, Kong KL, Baker JP, Hutchings P, Elliot TSJ, et al: Is selective bowel decontamination of the digestive tract beneficial in liver transplant patients? Interim results of a prospective, randomized trial. Trans Proc 1991, 95:273-278.
22. Arnow PM, Carandang GC, Zabner R, Irwin ME: Randomized controlled trial of selective bowel decontamination for prevention of infections following liver transplantation. Clin Infect Dis 1996, 22:997-1003.
23. Singh N, Gayowski T, Wagener MM, Marino IR: Bloodstream infections in liver transplant recipients receiving tacrolimus. Clin Transplant 1997, 11:275-281.
24. Chang FY, Singh N, Gayowski T, Drenning SD, Wagener MM, Marino IR: Staphylococcus aureus nasal colonization and association with infections in liver transplant recipients. Transplantation 1998, 65:1169-1172. This prospective study is the first to demonstrate clearly the added morbidity of methicillin-resistant S. aureus colonization in the liver recipient.
25. Linden PK, Pasculle AW, Manez R, Kramer DJ, Fung JJ, Pinna AD, Kusne S: Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin E. faecium. Clin Infect Dis 1996, 22:663-670.
26. Papanicolaou GA, Meyers BR, Meyers J, Mendelson MH, Lou W, Emre S, et al: Nosocomial infections with vancomycin-resistant Enterococcus faecium in liver transplant recipient: risk factors for acquisition and mortality. Clin Infect Dis 1996, 23:760-766.
27. Newell KA, Millis JM, Arnow PM, Bruce DS, Woodle ES, Cronin DC, et al: Incidence and outcome of infection by vancomycin-resistant Enterococcus following orthotopic liver transplantation. Transplantation 1998, 63:439-442.
28. Dominquez EA, David JC, Langnas AN, Winfield B, Cavalieri SJ, Rupp ME: An outbreak of vancomycin-resistant Enterococcus faecium in liver transplant recipients. Liver Transpl Surg 1997, 3:586-590.
29. Linden PK, Pokrywka M, Krystofiak S, Posey K, McCoy B, Pasculle AW, et al: The effect of ICU cohorting on the cross infection rates of vancomycin-resistant Enterococcus faecium. Crit Care Med 1994, 22:A228.
30. Linden PK, Pasculle AW, McDevitt D, Kramer DJ: Effect of quinupristin/dalfopristin on the outcome of vancomycin-resistant Enterococcus faecium bacteraemia: comparison with a control cohort. J Antimicrob Chemother 1997, 39(Suppl A):145-151.
31. Meyers BR, Halpern M, Sheiner P, Mendelson MH, Neibart E, Miller C: Tuberculosis in liver transplant patients. Transplantation 1994, 58:301-306.
32. Aguado JM, Herrero JA, Gavalda J, Torre-Cisneros J, Blanes M, Rufi G, et al: Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Spanish Transplantation Infection Study Group, GESITRA. Transplantation 1997, 63:1278-1286.
33. Schluger LK, Sheiner PA, Jonas M, Guarrera JV, Fiel IM, Meyers B, Berk PD: Isoniazid hepatotoxicity after orthotopic liver transplantation. Mt Sinai J Med 1996, 63:364-369.
34. Torre-Cisneros J, de la Mata M, Rufian S, Villanueva Marcos JL, Gutierrez Aroca J, Casal M, et al: Importance of surveillance mycobacterial cultures after liver transplantation. Transplantation 1995, 60:1054-1055.
35. Prodinger WM, Bonatti H, Allerberger F, Wewalka G, Harrison TG, Aichberger C, et al: Legionella pneumonia in transplant recipients: a cluster of cases of eight years duration. J Hosp Infect 1994, 26:191-202.
36. Singh N, Gayowski T, Wagener M, Marion IR, Yu VL: Pulmonary infections in liver transplant recipients receiving tacrolimus: changing patterns of microbial etiologies. Transplantation 1996, 61:396-401.
37. Vereerstraten P, Stolear JC, Schoutens-Serruys S, Maes N, Thus JP, Liesnard C, et al: Erythromycin prophylaxis for Legionnaire's disease in immunosuppressed patients in a contaminated hospital environment. Transplantation 1986, 41:52-54.
38. Collins LA, Samore MH, Roberts MS, Luzzati R, Jenkins RL, Lewis WD, Karchmer AW: Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis 1994, 170:644-652.
39. Tollemar J, Ericzson B-G: Invasive Candida albicans infections in orthotopic liver graft recipients: incidence and risk factors. Clin Transplant 1991, 5:306-312.
40. Patel R, Portela D, Badley AD, Harmsen WAS, Larson-Keller JJ, Ilstrup DM, et al: Risk factors for invasive Candida and non-Candida fungal infections after liver transplantation. Transplantation 1996, 62:926-934.
41. Castaldo P, Stratta RJ, Wood P, Markin RS, Patil KD, Shaefer MS, et al: Clinical spectrum of fungal infections after orthotopic liver transplantation. Arch Surg 1991, 126:149-156.
42. Kusne S, Tobin D, Pasculle AW, Van Thiel DH, Ho M, Starzl TE: Candida carriage in the alimentary tract of liver transplant candidates. Transplantation 1994, 57:398-402.
43. Tollemar J, Ericson B-G, Holmberg K, Andersson J: The incidence and diagnosis of invasive fungal infection in liver transplant recipients. Transplant Proc 1990, 22:242-244.
44. Winston DJ, Pakrasi A, Busuttil RW: Fluconazole prophylaxis of fungal infections in liver transplant recipients: results of a placebo-controlled, double-blind trial [Abstract 146]. The Ninth International Symposium on Infections in the Immunocompromised Host, Assisi, Italy, June 23-26, 1996.
45. Lumbreras C, Cuervas-Mons V, Jara P, del Palacio A, Turrion VS, Barrios C, et al: Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation. J Infect Dis 1996, 174:583-588.
46. Fortun J, Lopez-San Roman A, Velasco JJ, Sanchez-Sousa A, de Vicente E, Nuno J, et al: Selection of Candida glabrata strains with reduced susceptibility to azoles in four liver transplant patients with invasive candidiasis. Eur J Clin Microbiol Dis 1997, 16:314-318.
47. Linden PK, Kramer DJ, Mazariegos G, Marsh W, Casavilla A, Pinna AD, et al: Low dose amphotericin B (LDA) for the prophylaxis of serious Candida infection in high-risk liver recipients [Abstract J-47]. Proceedings 36th International Conference of Antimicrobial Agents and Chemotherapy, New Orleans: American Society for Microbiology, p 227.
48. Tollemar J, Hockerstedt K, Ericzon BG, Jalanko H, Ringden O: Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. Transplantation 1995, 59:45-50.
49. Denning DW: Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996, 23:608-615.
50. Horvath JA, Dummer JA: The use of respiratory-tract cultures in the diagnosis of invasive pulmonary aspergillosis. Am J Med 1996, 100:171-178.
51. Brown RS Jr, Lake JR, Katzman BA, Ascher NL, Somberg KA, Emond JC, Roberts JP: Incidence and significance of Aspergillus cultures following liver and kidney transplantation. Transplantation 1996, 61:666-669.
52. Hopwood V, Johnson EM, Cornish JM, Foot AB, Evans EG, Warnock DW: Use of the Pastorex aspergillus antigen latex agglutination test for the diagnosis of invasive aspergillosis. J Clin Pathol 1995, 48:210-213.
53. Braun F, Ruchel R, Lorf T, Canelo R, Muller A, Sattler B, Ringe B: Is liposomal amphotericin B (Ambisome) an effective prophylaxis of mycotic infections after liver transplantation? Trans Proc 1998, 30:1481-1483.
54. Hayes MJ, Torzillo PG, Sheil GR, MaCaughan GW: Pneumocystis carinii pneumonia after liver transplantation in adults. Clin Transplant 1994, 8:499-503.
55. Fishman JA, Rubin RH: Infections in organ-transplant recipients. N Engl J Med 1998, 338:1741-1751. This concise, well-written article on the current status of posttransplant infection in solid-organ recipients is by an outstanding expert in the field.
56. Jabbour N, Reyes J, Kusne S, Martin M, Fung J: Cryptococcal meningitis after liver transplantation. Transplantation 1996, 61:146-149.
57. Singh N, Dummer JS, Kusne S, Berinig MK, Armstrong A, Makawoka L, et al: Infections with cytomegalovirus and other herpesvirus in 121 liver transplant recipients: transmission by donated organ the effect of OKT3 antibodies. J Infect Dis 1988, 158:124-131.
58. Kusne S, Schwartz M, Breinig MK, Dummer JS, Lee E, Selby R, et al: Herpes simplex virus hepatitis after solid organ transplantation in adults. J Infect Dis 1991, 163:1001-1007.
59. Haagsma EB, Klompmaker IJ, Grond J, Bijeveld MA, The TH, Schirm J, et al: Herpes virus infections after liver transplantation. Transplant Proc 1987, 19:4054-4056.
60. O'Grady JG, Alexander GJM, Sutherland S, Donaldosn PT, Harvey F, Portmann B, et al: Cytomegalovirus infection and donor/recipient HLA antigen: interdependent co-factors in pathogenesis of vanishing bile duct syndrome after liver transplantation. Lancet 1988, 2:302-305.
61. van den Berg AP, Klompmaker IJ, Haagsma EB, Peeters PM, Meerman L, Verwer R, et al: Evidence for an increased rate of bacterial infections in liver transplant patients with cytomegalovirus infection. Clin Transplant 1996, 10:224-231.
62. Falagas ME, Snydman DR, Griffith J, Werner BG: Exposure to cytomegalovirus from the donated organ is a risk factor for bacteremia in orthotopic liver transplant recipients: Boston Center for Liver Transplantation CMVIG Study Group. Clin Infect Dis 1996, 23:468-474.
63. de Otero J, Gavalda J, Murio E, Vargas V, Calico I, Llopart L, et al: Cytomegalovirus disease as a risk factor for graft loss and death after orthotopic liver transplantation. Clin Infect Dis 1998, 26:865-870.
64. Falagas ME, Snydman DR, Griffith J, Ruthazer R, Werner BG: Effect of cytomegalovirus infection status on first-year mortality rates among orthotopic liver transplant recipients. The Boston Center for Liver Transplantation CMVIG Study Group. Ann Intern Med 1997, 126:275-279.
65. Falagas ME, Arbo M, Ruthazer R, Griffith JL, Werner BG, Rohrer R, et al: Cytomegalovirus disease is associated with increased cost and hospital length of stay amongst orthotopic liver transplant recipients. Transplantation 1997, 63:1595-1601.
66. Couchoud C, Cucherat M, Haugh M, Pouteil-Noble C: Cytomegalovirus prophylaxis with antiviral agents in solid organ transplantation. Transplantation 1998, 65:641-647. This meta-analysis of 13 prospective, randomized controlled trials assesses the efficacy of antiviral agents to prevent CMV infection and disease in solid-organ transplant recipients.
67. Gavalda J, de Otero J, Murio E, Vargas V, Rossello J, Calico I, et al: Two grams daily of oral acyclovir reduces the incidence of cytomegalovirus disease in CMV-seropositive liver transplant recipients. Transplant Int 1997, 10:462-465.
68. Martin M, Manez R, Linden P, Estores D, Torre-Cisneros J, Kusne S, et al: A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation 1994, 58:779-785.
69. Badley AD, Seaberg EC, Porayko MK, Wiesner RH, Keating MR, Wilhelm MP, et al: Prophylaxis of cytomegalovirus infection in liver transplantation: a randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database. Transplantation 1997, 64:66-73.
70. Seu P, Winston DJ, Holt CD, Kaldas F, Busuttil RW: Long term ganciclovir prophylaxis for successful prevention of primary cytomegalovirus (CMV) disease in CMV-seronegative liver transplant recipients with CMV-seropositive donors. Transplantation, 1997, 64:1614-1617.
71. Snydman DR, Werner BG, Dougherty NN, et al: Cytomegalovirus immune globulin prophylaxis in liver transplantation: a randomized double-blind, placebo-controlled trial. Ann Intern Med 1993, 119:984-991.
72. Gane E, Saliba F, Valdecasas GJ, O'Grady J, Pescovitz MD, Lyman S, Robinson CA: Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group. Lancet 1997, 350:1729-1733.
73. Grossi P, Kusne S, Rinaldo C, St. George K, Magnone M, Rakela J, et al: Guidance of ganciclovir therapy with pp65 antigenemia in cytomegalovirus-free recipients of livers from seropositive donors. Transplantation 1996, 61:1659-1660.
74. Singh N, Yu VL, Mieles L, Wagener MM, Miner RC, Gayowski T: High dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients: a randomized trial. Ann Intern Med 1994, 120:375-381.
75. Winston DJ, Imagawa DK, Holt CD, Kaldas F, Shaked A, Bussutil RW: Long-term ganciclovir prophylaxis eliminates serious cytomegalovirus disease in liver transplants receiving OKT3 therapy for rejection. Transplantation 1995, 60:1357-1360.
76. Falagas ME, Snydman DR, Ruthazer R, Werner BG, Griffith J: Surveillance cultures of blood, urine, and throat specimens are not valuable for predicting cytomegalovirus disease in liver transplant recipients. Boston Center for Liver Transplantation Cytomegalovirus Immune Globulin Study Group. Clin Infect Dis 1997, 24:824-829.
77. Abecassis MM, Koffron AJ, Kaplan B, Buckingham M, Muldoon JP, Cribbins AJ, et al: The role of PCR in the diagnosis and management of CMV in solid organ recipients: what is the predictive value for the development of disease and should PCR be used to guide antiviral therapy? Transplantation 1997, 63:275-279.
78. Boeckh M, Boivin G: Quantitation of cytomegalovirus: methodologic aspects and clinical applications. Clin Microbiol Rev 1998, 11:533-554. This is a comprehensive review of the rapidly emerging technology for the quantification of CMV viral load and its clinical application for monitoring CMV infection and disease in organ recipients.
79. Manez R, Breinig MC, Linden P, Wilson J, Torre-Cisneros J, Kusne S, et al: Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease. J Infect Dis 1997, 176:1462-1467.
80. Riddler SA, Breinig MC, McKnight JLC: Increased levels of circulating Epstein-Barr virus EBV infected lymphocytes and decreased EBV nuclear antigen are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. Blood 1994, 3:972-984.
81. Darenkov IA, Marcarelli MA, Basadonna GP, Friedman AL, Lorber KM, Howe JG, et al: Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy. Transplantation 1997, 64:848-852.
82. Green M, Kaufmann M, Wilson J, Reyes J: Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children. Clin Infect Dis 1997, 24:1344-1349.
83. Samuel D, Bismuth A, Mathiew D, Arulnaden JL, Reynes M, Benhamou JP, et al: Passive immunoprophylaxis after liver transplantation in HBsAG-positive patients. Lancet 1991, 337:813-815.
84. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamoc JP, Bismuth H: Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993,329:1842-1847.
85. Nymann T, Shokouh-Amiri MH, Vera SR, Riely CA, Alloway RR, Gaber AO: Prevention of hepatitis B recurrence with indefinite hepatitis B immune globulin (HBIG) prophylaxis after liver transplantation. Clin Transplant 1996, 10:663-667.
86. McGory RW, Ishitoni MB, Oliveira WM, Stevenson WC, McCullough CS, Dickson RC, et al: Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996, 61:1358-1364.
87. Ishitani M, McGory R, Dickson R, Caldwell S, Bickston S, McCullough C, et al: Retransplantation of patients with severe posttransplant hepatitis B in the first allograft. Transplantation 1997, 64:410-414.
88. Lowell JA, Burgess S, Shenoy S, Pters M, Howard TK: Mercury poisoning associated with hepatitis-B immunoglobulin. Lancet 1996, 347:840.
89. Ghany MG, Ayola B, Villamil FG, Gish RG, Rojter S, Vierling JM, Lok AS: Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 1998, 27:213-222.
90. Singh N, Gayowski T, Wannstedt CF, Wagener MM, Marino IR: Pretransplant famciclovir as prophylaxis for hepatitis B virus recurrence after liver transplantation. Transplantation 1997, 63:1415-1419.
91. Grellier L, Mutimer D, Ahmed M, Brown D, Burroughs AK, Rolles IC, et al: Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996, 348:1212-1215.
92. Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahl H, et al: Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997, 349:20-22.
93. Dodson SF, Issa S, Araya V, Gayowski T, Pinna A, Eghtesad B, et al: Infectivity of hepatic allografts with antibodies to hepatitis B virus. Transplantation 1997, 64:1582-1584.
94. Dickson RC, Everhart JE, Lake JR, Wei Y, Seaberg EC, Wiesner RH, et al: Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology 1997, 113:1668-1674.
95. Rosen HR, O'Reilly PM, Shackleton CR, McDiarmid S, Holt C, Busuttil RW, Martin P: Graft loss following liver transplantation in patients with chronic hepatitis C. Transplantation 1996, 62:1773-1776.
96. Singh N, Gayowski T, Wannstedt CF, Shakil AO, Wagener MM, Fung JJ, Marino IR: Interferon-alpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: a prospective, randomized, controlled trial. Transplantation 1998, 65:82-86.
97. Gane EJ, Lo SK, Riordan SM, Portmann BC, Lau JY, Naoumov NV, Williams R: A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation. Hepatology 1998, 27:1403-1407.
98. Lautenschlager I, Hockerstedt K, Linavuori K, Taskinen E: Human herpesvirus-6 infection after liver transplantation. Clin Infect Dis 1998, 26:702-707.
99. Singh N, Carrigan DR, Gayowski T, Marino IR: Human herpesvirus-6 infection in liver transplant recipients: documentation of pathogenjcity. Transplantation 1997, 64:674-678.
100. Ndimbie OK, Frezza E, Jordan JA, Koch W, van Thiel DH: Parvovirus B19 in anemic liver transplant recipients. Clin Diagn Lab Immunol 1996, 3:756-760.
101. Chang FY, Singh N, Gayowski T, Marino IR: Parvovirus B19 infection in a liver transplant recipient: case report and review in organ transplant recipients. Clin Transplant 1996, 10:243-247.
102. Ramage JK, Hale A, Gane E, Cohen B, Boyle M, Mufit G, Williams R: Parvovirus B19-induced red cell aplasia treated with plasmapheresis and immunoglobulin. Lancet 1994, 343:667-668.